173 related articles for article (PubMed ID: 35726331)
21. [Changes and clinical significance of γδT cells in peripheral blood of patients with chronic hepatitis B during pegylated interferon α-2a treatment].
Liu K; Shen YX; Ling N; Lei Y; Hu P; Ren H; Chen M
Zhonghua Gan Zang Bing Za Zhi; 2018 May; 26(5):365-370. PubMed ID: 29996205
[No Abstract] [Full Text] [Related]
22. [Efficacy of 104-week sequential therapy with telbivudine or entecavir in HBeAg-positive chronic hepatitis B patients with suboptimal responses to 24-week therapy with pegylated interferon-α-2a].
Luo XD; Chen XP; Chen R; Chen XF; Huang J
Zhonghua Gan Zang Bing Za Zhi; 2016 Apr; 24(4):241-5. PubMed ID: 27470620
[TBL] [Abstract][Full Text] [Related]
23. HBeAg-negative chronic hepatitis B: why do I treat my patients with pegylated interferon-alfa?
Vlachogiannakos J; Papatheodoridis GV
Liver Int; 2014 Feb; 34 Suppl 1():127-32. PubMed ID: 24373089
[TBL] [Abstract][Full Text] [Related]
24. Clinical cure induced by pegylated interferon α-2b in the advantaged population of chronic hepatitis B virus infection: a retrospective cohort study.
Wen C; Wang Y; Tian H; Lei Y; Wang Z; Cai D; Zhou Z; Shi X
Front Cell Infect Microbiol; 2023; 13():1332232. PubMed ID: 38292859
[TBL] [Abstract][Full Text] [Related]
25. Peg-interferon alpha add-on Tenofovir disoproxil fumarate achieved more HBsAg loss in HBeAg-positive chronic hepatitis B naïve patients.
Li J; Qu L; Sun X; Liu Y; Gong Q; Yu D; Zhang D; Jiang J; Chen J; Wei D; Han Y; Gao Y; Zhang Q; She W; Chen L; Zhang J; Zhang X
J Viral Hepat; 2021 Oct; 28(10):1381-1391. PubMed ID: 34228855
[TBL] [Abstract][Full Text] [Related]
26. HBsAg and HBeAg in the prediction of a clinical response to peginterferon α-2b therapy in Chinese HBeAg-positive patients.
Yang S; Xing H; Wang Y; Hou J; Luo D; Xie Q; Ning Q; Ren H; Ding H; Sheng J; Wei L; Chen S; Fan X; Huang W; Pan C; Gao Z; Zhang J; Zhou B; Chen G; Wan M; Tang H; Wang G; Yang Y; Xu D; Dong P; Wang Q; Wang J; Bognar FA; Xu D; Cheng J
Virol J; 2016 Oct; 13(1):180. PubMed ID: 27793166
[TBL] [Abstract][Full Text] [Related]
27. [Quantifiable changes in HBeAg expression predict therapeutic efficacy of peg-interferon alfa-2a in patients with HBeAg-positive chronic hepatitis B].
Ji YJ; Li FF; Ren WH; Zhu YH; Qin CY
Zhonghua Gan Zang Bing Za Zhi; 2013 May; 21(5):335-9. PubMed ID: 24025132
[TBL] [Abstract][Full Text] [Related]
28. [Factors influencing the curative effect in patients with HBeAgpositive chronic hepatitis B treated with peg-interferon α-2a].
Chen J; Zheng Q; Jiang J; Zheng J
Zhong Nan Da Xue Xue Bao Yi Xue Ban; 2012 Jul; 37(7):714-9. PubMed ID: 22886227
[TBL] [Abstract][Full Text] [Related]
29. Effect of switching from treatment with nucleos(t)ide analogs to pegylated interferon α-2a on virological and serological responses in chronic hepatitis B patients.
He LT; Ye XG; Zhou XY
World J Gastroenterol; 2016 Dec; 22(46):10210-10218. PubMed ID: 28028369
[TBL] [Abstract][Full Text] [Related]
30. [Low-levels of HBsAg quantification at 48-week in HBeAg-negative chronic hepatitis B patients are the advantageous population for HBsAg clearance].
Yan YJ; Wang XX; Cao ZH; Lu JF; Jin Y; He ZM; Geng N; Ren S; Ma LN; Chen XY
Zhonghua Gan Zang Bing Za Zhi; 2018 Nov; 26(11):813-818. PubMed ID: 30616314
[No Abstract] [Full Text] [Related]
31. Role of HBsAg decline in patients with chronic hepatitis B HBeAg-negative and E genotype treated with pegylated-interferon.
Boglione L; Cusato J; Cariti G; Di Perri G; D'Avolio A
Antiviral Res; 2016 Dec; 136():32-36. PubMed ID: 27793564
[TBL] [Abstract][Full Text] [Related]
32. Dynamic Changes of Cytokine Profiles and Virological Markers Associated With HBsAg Loss During Peginterferon Alpha-2a Treatment in HBeAg-Positive Chronic Hepatitis B Patients.
Li M; Zhang L; Xie S; Sun F; Zeng Z; Deng W; Jiang T; Bi X; Lin Y; Yang L; Lu Y; Shen G; Liu R; Wu S; Chang M; Hu L; Dong J; Yi W; Xie Y
Front Immunol; 2022; 13():892031. PubMed ID: 35603222
[TBL] [Abstract][Full Text] [Related]
33. Treatment with Peg-interferon alpha-2b for HBeAg-positive chronic hepatitis B: HBsAg loss is associated with HBV genotype.
Flink HJ; van Zonneveld M; Hansen BE; de Man RA; Schalm SW; Janssen HL;
Am J Gastroenterol; 2006 Feb; 101(2):297-303. PubMed ID: 16454834
[TBL] [Abstract][Full Text] [Related]
34. Peginterferon alpha-based therapy for chronic hepatitis B focusing on HBsAg clearance or seroconversion: a meta-analysis of controlled clinical trials.
Li WC; Wang MR; Kong LB; Ren WG; Zhang YG; Nan YM
BMC Infect Dis; 2011 Jun; 11():165. PubMed ID: 21651820
[TBL] [Abstract][Full Text] [Related]
35. Phase IV randomized clinical study: Peginterferon alfa-2a with adefovir or entecavir pre-therapy for HBeAg-positive chronic hepatitis B.
Hsu CW; Su WW; Lee CM; Peng CY; Chuang WL; Kao JH; Chu HC; Huang YH; Chien RN; Liaw YF
J Formos Med Assoc; 2018 Jul; 117(7):588-597. PubMed ID: 29456079
[TBL] [Abstract][Full Text] [Related]
36. [Efficacy of combination therapy with peginterferon alfa-2alpha and bicyclol in chronic hepatitis B with high ALT levels].
Ni Q; Tian-Sheng X; Min-Wei L; Ke-Zhou L
Zhonghua Shi Yan He Lin Chuang Bing Du Xue Za Zhi; 2012 Apr; 26(2):114-6. PubMed ID: 23002549
[TBL] [Abstract][Full Text] [Related]
37. Add-on peg-interferon leads to loss of HBsAg in patients with HBeAg-negative chronic hepatitis and HBV DNA fully suppressed by long-term nucleotide analogs.
Ouzan D; Pénaranda G; Joly H; Khiri H; Pironti A; Halfon P
J Clin Virol; 2013 Dec; 58(4):713-7. PubMed ID: 24183313
[TBL] [Abstract][Full Text] [Related]
38. HBV DNA and HBsAg: Early Prediction of Response to Peginterferon α-2a in HBeAg-Negative Chronic Hepatitis B.
Zhang C; Yang Z; Wang Z; Dou X; Sheng Q; Li Y; Han C; Ding Y
Int J Med Sci; 2020; 17(3):383-389. PubMed ID: 32132873
[No Abstract] [Full Text] [Related]
39. Higher TP53BP2 expression is associated with HBsAg loss in peginterferon-α-treated patients with chronic hepatitis B.
Guan G; Zhang T; Ning J; Tao C; Gao N; Zeng Z; Guo H; Chen CC; Yang J; Zhang J; Gu W; Yang E; Liu R; Guo X; Ren S; Wang L; Wei G; Zheng S; Gao Z; Chen X; Lu F; Chen X
J Hepatol; 2024 Jan; 80(1):41-52. PubMed ID: 37858684
[TBL] [Abstract][Full Text] [Related]
40. The efficacy of pegylated interferon alpha-2a and entecavir in HBeAg-positive children and adolescents with chronic hepatitis B.
He Y; Zhou Y; Wang H; Peng X; Chang Y; Hu P; Ren H; Xu H
BMC Pediatr; 2022 Jul; 22(1):426. PubMed ID: 35854256
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]